Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD

Annals of the American Thoracic Society

Volumn 12, Issue 1, 2015, Pages 27-34

  Crim, Courtney ^a   Dransfield, Mark T ^b   Bourbeau, Jean ^c   Jones, Paul W ^d   Hanania, Nicola A ^e   Mahler, Donald A ^f   Vestbo, Jørgen ^g,h,i   Wachtel, Andrew ^j   Martinez, Fernando J ^k   Barnhart, Frank ^a   Lettis, Sally ^l   Calverley, Peter M A ^m  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j Southern California Institute for Respiratory Diseases   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

^l GLAXOSMITHKLINE   (United Kingdom)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

Chronic obstructive pulmonary disease; Corticosteroids; Pneumonia

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; FLUTICASONE FUROATE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PARENCHYMA CELL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BENZYL ALCOHOLS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 84922423567     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201409-413OC     Document Type: Article

References (32)

1. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39:1642-1650.
2. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-1133.
3. Crim C, Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
4. Lieberman D, Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122:1264-1270.
5. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia: a prospective study of a general population. Eur Respir J 1995;8:1694-1698.
6. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-1108.
7. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a doubleblind, randomized study. Respir Med 2012;106:257-268.
8. Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010;19:109-117.
9. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104:246-252.
10. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-166.
11. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
12. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:CD010115.
13. Chen D, Restrepo MI, Fine MJ, Pugh MJV, Anzueto A, Metersky ML, Nakashima B, Good C, Mortensen EM. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-316.
14. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41.
15. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-223.
16. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
18. Mittl RL Jr, Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994;149:630-635.
19. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
20. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
21. McGarvey LP, Matthias J, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
22. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009;6:320-329.
23. Cheng SL, Su KC, Wang HC, Perng DW, Yang PC. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des Devel Ther 2014;8:601-607.
24. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-195.
25. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
26. Wunderink RG, Waterer GW. Community-acquired pneumonia. N Engl J Med 2014;370:543-551.
27. Patterson CM, Morrison RL, D'Souza A, Teng XS, Happel KI. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 2012;13:40.
28. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW. Pharmacological properties of the enhancedaffinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-L667.
29. O' Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J 2014;43:773-782.
30. Calverley PMA, Stockley RA, Seemungal TAR, Hagan G, Willits LR, Riley JH, Wedzicha JA; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-512.
31. File TM Jr, Monte SV, Schentag JJ, Paladino JA, Klugman KP, Lavin B, Yu VL, Singer ME, Adelman MH. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. Int J Antimicrob Agents 2009;33:58-64.
32. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.